ecstasy
Last reviewed 01/2018
- ecstasy - name given by its users to 3,4-methylene-dioxymethamphetamine
(MDMA)
- second most commonly used controlled drug (after cannabis) in Europe
- MDMA is a ring-substituted amphetamine derivative
- related to
the hallucinogenic compound mescaline
- does not produce the profound sensory disruptions or hallucinations associated with classical hallucinogens such as lysergic acid diethylamine (LSD)e
- increases emotional sensitivity and
empathy
- also MDMA use associated with a loss of inhibitions; reduced anxiety; increased sense of closeness with other people
- pharmacology
- action
in the central nervous system is complex
- major effects on serotonin (5-hydroxytryptamine [5-HT]) pathways - however also affects two other major transmitter systems in the brain: dopamine (DA) and noradrenaline
- use of MDMA causes an acute
and rapid increase in extracellular 5-HT
- causes a marked depletion of 5-HT from brain tissue in the first few hours following drug administration
- in
rat models 5-HT levels recover within 24 h after a single dose of MDMA; however
higher doses of MDMA can result in sustained depletion of 5-HT that can last for
up to 12 months
- MDMA also blocks the activity of tryptophan hydroxylase
(rate-limiting enzyme in the biosynthesis of 5-HT)
- this effect occurs within 15 min following administration - can last for up to two weeks
- MDMA also blocks the activity of tryptophan hydroxylase
(rate-limiting enzyme in the biosynthesis of 5-HT)
- action
in the central nervous system is complex
- acute
toxic effects
- malignant hyperthermia - this syndrome of persistent hyperthermia
which leads to the rhabdomyolysis with subsequent renal and other organ failure
- mechanism for this is unknown - there may be a possible role for uncoupling protein-3, a mitochondrial protein known to play a role in thermogenesis
- malignant hyperthermia - this syndrome of persistent hyperthermia
which leads to the rhabdomyolysis with subsequent renal and other organ failure
- neuropsychological
effects of depletion of brain levels of 5-HT
- following MDMA use
- subjective
effects reported are euphoria, changes in perception (sound and light), a reduction
in defensiveness (negative affect), emotional openness, empathy and a reduction
of inhibitions
- effects are likely to be mediated via the 5-HT-system
- the
use of ectasy does not leave the user with a "neutral" mood
- following ecstasy use there is an ‘offset’ period - during this period there is a worsening of mood - this low mood persists for several days (known as the ‘midweek blues’)
- it has been suggested that there may be an increase in aggression/anger/anxiety occurs after taking ecstasy - tends to peak four days after taking the drug
- effects of ecstasy on mood appear to be reversible
- there is study evidence that indicate that depression, impulsivity, and sensation seeking do not predict first time ecstasy use in a population of young adults with the intention to start using ecstasy (2)
- subjective
effects reported are euphoria, changes in perception (sound and light), a reduction
in defensiveness (negative affect), emotional openness, empathy and a reduction
of inhibitions
- following MDMA use
- there is evidence from studies of long term MDMA use of long-term (weeks to months) impairments in memory and learning; in particular, working memory, planning ability, executive control and cognitive impulsivity
The effects of ecstasy on the cardiovascular system are described in the linked item.
Notes:
- a study investigating
the safety of single or low dose of ecstasy has been undertaken (3):
- the study showed no differences in metabolites concentrations before and after ecstasy use and found no indications for major neuronal damage after a single or low dose of ecstasy use in first time ecstasy users. Howeve the authors stated that, because there might be various factors that play a role in individual vulnerability for acute and long-term effects of ecstasy, it is not possible to state that the use of a single or low dose of ecstasy is totally safe
Reference:
- Curr Opin Pharmacol. 2005 Feb;5(1):79-86
- J Psychopharmacol. 2006 Mar;20(2):226-35.
- Europ Neuropsychopharm 2006; 16(1): S79-S80.